Andrew J Piper-Vallillo
Overview
Explore the profile of Andrew J Piper-Vallillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang A, Piper-Vallillo A, Mak R, Lanuti M, Muzikansky A, Rotow J, et al.
Oncologist
. 2024 May;
29(7):609-618.
PMID: 38761385
Background: The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic oncogene-driven non-small cell lung cancer (NSCLC) is established, but it remains unknown how best to integrate TKIs with...
2.
Viray H, Piper-Vallillo A, Widick P, Academia E, Shea M, Rangachari D, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539415
Osimertinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that is used for first-line therapy in mutated non-small cell lung cancer (NSCLC) based on the results...
3.
Sentana-Lledo D, Viray H, Piper-Vallillo A, Widick P, Rangachari D, Wilson J, et al.
Lung Cancer
. 2022 Sep;
172:124-126.
PMID: 36075183
Objectives: Neoadjuvant therapy prior to surgical resection for locally advanced lung cancer has evolved to incorporate systemic cytotoxic chemotherapy +/- immunotherapy +/- radiotherapy. The role of neoadjuvant precision therapies remains...
4.
White M, Piper-Vallillo A, Gardner R, Cunanan K, Neal J, Das M, et al.
Clin Lung Cancer
. 2021 Dec;
23(3):e210-e221.
PMID: 34887193
Introduction: Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown. Materials...
5.
Piper-Vallillo A, Kobayashi S, Costa D
JTO Clin Res Rep
. 2021 Sep;
2(3):100133.
PMID: 34589996
No abstract available.
6.
Piper-Vallillo A, Costa D, Sabe M, Asnani A
JACC CardioOncol
. 2021 Aug;
2(1):119-122.
PMID: 34396216
No abstract available.
7.
Piper-Vallillo A, Sequist L
JACC CardioOncol
. 2021 Aug;
1(2):179-181.
PMID: 34396180
No abstract available.
8.
Klein I, Rosenberg S, Reynolds K, Zubiri L, Rosovsky R, Piper-Vallillo A, et al.
Oncologist
. 2021 Apr;
26(8):685-693.
PMID: 33856099
Background: Early reports suggested increased mortality from COVID-19 in patients with cancer but lacked rigorous comparisons to patients without cancer. We investigated whether a current cancer diagnosis or cancer history...
9.
Xu W, Piper-Vallillo A, Bindal P, Wischhusen J, Patel J, Costa D, et al.
Cancer Med
. 2021 Feb;
10(5):1545-1549.
PMID: 33560590
Background: For cancer patients, coronavirus disease 19 (COVID-19) infection can lead to delays in cancer therapy both due to the infection itself and due to the need to minimize exposure...
10.
Piper-Vallillo A, Halbert B, Rangachari D, Kobayashi S, Costa D
JTO Clin Res Rep
. 2020 Nov;
1(4):100071.
PMID: 33225315
No abstract available.